Atorvastatin: a review of its pharmacological properties and use in familial hypercholesterolemia

Bibliography

• Bourbon M, Alves AC, Medeiros AM, Silva S, Soutar AK; Investigators of Portuguese FH Study: Familial hypercholesterolaemia in Portugal. Atherosclerosis 196(2), 633–642 (2008).
   Google Scholar
• Ajmal M, Ahmed W, Sadeque A et al.: Identification of a recurrent insertion mutation in the LDLR gene in a Pakistani family with autosomal dominant hypercholesterolemia. Mol. Biol. Rep. DOI: 10.1007/s11033-010-0043-0 (2010) (Epub ahead of print).
   Google Scholar
• Marks D, Thorogood M, Neil HA, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168(1), 1–14 (2003).
   Google Scholar
• ▪▪ Essential for a comprehensive overview of familial hypercholesterolemia (FH).
   Google Scholar
• Yang KC, Su YN, Shew JY et al.: LDLR and APOB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J. Formos. Med. Assoc. 106(10), 799–807 (2007).
   Google Scholar
• Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE: Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann. Hum. Genet. 72(Pt 4), 485–498 (2008).
   Google Scholar
• Taylor A, Wang D, Patel K et al.: Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin. Genet. 77(6), 572–580 (2010).
   Google Scholar
• Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1(6), 445–466 (1992).
   Google Scholar
• ▪▪ Discusses the primary mechanism for the evidence of FH.
   Google Scholar
• Keller C: LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler. Suppl. 10(5), 21–26 (2009).
   Google Scholar
• Bhagwat PV, Tophakhane RS, Kudligi C, Noronha TM, Thirunavukkarasu A: Familial combined hypercholesterolemia type II b presenting with tuberous xanthoma, tendinous xanthoma and pityriasis rubra pilaris-like lesions. Indian J. Dermatol. Venereol. Leprol. 76(3), 293–296 (2010).
   Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 303(6807), 893–896 (1991).
   Google Scholar
• Gotto AM Jr: Lipid-lowering therapy for the primary prevention of coronary heart disease. J. Am. Coll. Cardiol. 33(7), 2078–2082 (1999).
   Google Scholar
• Wierzbicki AS, Viljoen A: Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Drug Saf. 33(2), 115–125 (2010).
   Google Scholar
• Ascaso JF: [Advances in cholesterol-lowering interventions.] Endocrinol. Nutr. 57(5), 210–219 (2010).
   Google Scholar
• Higashikata T, Mabuchi H: Long-term effect of low-density lipoprotein apheresis in patients with heterozygous familial hypercholesterolemia. Ther. Apher. Dial. 7(4), 402–407 (2003).
   Google Scholar
• Richter WO, Donner MG, Höfling B, Schwandt P: Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 47(7), 863–868 (1998).
   Google Scholar
• Mabuchi H, Koizumi J, Shimizu M et al.: Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82(12), 1489–1495 (1998).
   Google Scholar
• Yee HS, Fong NT: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann. Pharmacother. 32(10), 1030–1043 (1998).
   Google Scholar
• One of the earliest observations of the use of atorvastatin in primary hypercholesterolemia.
   Google Scholar
• Roth BD: The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem. 40, 1–22 (2002).
   Google Scholar
• Wierzbicki AS: Atorvastatin. Expert Opin. Pharmacother. 2(5), 819–830 (2001).
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495–1504 (2004).
   Google Scholar
• Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84(3), 413–428 (1999).
   Google Scholar
• Yin YM, Cui FD, Kim JS et al.: Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium. Drug Deliv. 16(1), 30–36 (2009).
   Google Scholar
• Lennernäs H: Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42(13), 1141–1160 (2003).
   Google Scholar
• Naoumova RP, Dunn S, Rallidis L et al.: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J. Lipid Res. 38(7), 1496–1500 (1997).
   Google Scholar
• ▪ Along with [40], demonstrates the potential biomolecular mechanisms as to why atorvastatin would be a superior compound in the treatment of FH.
   Google Scholar
• Athyros VG, Papageorgiou AA, Kontopoulos AG: Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 163(1), 205–206 (2002).
   Google Scholar
• McCrindle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J. Pediatr. 143(1), 74–80 (2003).
   Google Scholar
• Banyai S, Banyai M, Falger J et al.: Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis 159(2), 513–519 (2001).
   Google Scholar
• van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF: Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 89(8), 893–896 (2003).
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383–1389 (1994).
   Google Scholar
• Shepherd J, Cobbe SM, Ford I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301–1307 (1995).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335(14), 1001–1009 (1996).
   Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339(19), 1349–1357 (1998).
   Google Scholar
• Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279(20), 1615–1622 (1998).
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005–2016 (2003).
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al.; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 (2004).
   Google Scholar
• Buse J: Statin therapy in diabetes mellitus. Clin. Diabetes 21, 168–172 (2003).
   Google Scholar
• Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2(5), 205–207 (2001).
   Google Scholar
• Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl. 1), III50–III57 (2004).
   Google Scholar
• Hall JG: Gene therapy for familial hypercholesterolemia. Growth Genet. Horm. 11, 2 (1995).
   Google Scholar
• Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR: Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting up-regulation of cholesterol synthesis after apheresis and bile acid sequestrants. Circulation 94(1), 3410 (1996).
   Google Scholar
• ▪ Along with [24], demonstrates the potential biomolecular mechanisms as to why atorvastatin would be a superior compound in the treatment of FH.
   Google Scholar
• Naoumova RP, Marais AD, Mountney J et al.: Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 119(2), 203–213 (1996).
   Google Scholar
• Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR: Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38(10), 2071–2078 (1997).
   Google Scholar
• Castaño G, Mas R, Fernández L et al.: Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 20(2), 153–163 (2003).
   Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577–581 (2001).
   Google Scholar
• Stein EA: New evidence supporting aggressive lipid lowering. Postgrad. Med. 113(4 Suppl.), 31–40 (2003).
   Google Scholar
• McCormick LS, Black DM, Waters D, Brown WV, Pitt B: Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am. J. Cardiol. 80(9), 1130–1133 (1997).
   Google Scholar
• Pitt B, Waters D, Brown WV et al.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N. Engl. J. Med. 341(2), 70–76 (1999).
   Google Scholar
• Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E; HeFH Study Group: Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 92(11), 1287–1293 (2003).
   Google Scholar
• Brown SL, Raal FJ, Panz VR, Stevens BA, Veller MG: High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc. J. S. Afr. 15(2), 70–75 (2004).
   Google Scholar
• Trip MD, van Wissen S, Smilde TJ, Hutten BA, Stalenhoef AF, Kastelein JJ: Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. Am. J. Cardiol. 91(5), 604–606 (2003).
   Google Scholar
• Goldammer A, Wiltschnig S, Heinz G et al.: Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. Metabolism 51(8), 976–980 (2002).
   Google Scholar
• Geiss HC, Otto C, Schwandt P, Parhofer KG: Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 50(8), 983–988 (2001).
   Google Scholar
• van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ: Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am. J. Cardiol. 95(2), 264–266 (2005).
   Google Scholar
• Athyros VG, Papageorgiou AA, Demitriadis DS, Kontopoulos AG: Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia – a pilot study. Curr. Med. Res. Opin. 17(4), 267–272 (2001).
   Google Scholar
• Hoogerbrugge N: Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. J. Intern. Med. 244(2), 143–147 (1998).
   Google Scholar
• Larivière M, Lamarche B, Pirro M et al.: Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. Atherosclerosis 167(1), 97–104 (2003).
   Google Scholar
• ▪▪ Original research on the different components of LDL particles in the heterozygous form of FH.
   Google Scholar
• Davidson M, Ma P, Stein EA et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89(3), 268–275 (2002).
   Google Scholar
• Gaw A: A new reality: achieving cholesterol-lowering goals in clinical practice. Atheroscler. Suppl. 2(4), 5–8; discussion 8–11 (2002).
   Google Scholar
• Stein E, Strutt KL, Miller E, Southworth H: ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 37, 292A (2001).
   Google Scholar
• Stein E, Strutt KL, Miller E, Southworth H: Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C, achieves treatment goals more effectively that atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2(Suppl. 2), 90–176 (2001).
   Google Scholar
• Palcoux JB, Meyer M, Jouanel P, Vanlieferinghen P, Malpuech G: Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia. Ther. Apher. 6(2), 136–139 (2002).
   Google Scholar
• Geiss HC, Parhofer KG, Schwandt P: Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. J. Intern. Med. 245(1), 47–55 (1999).
   Google Scholar
• ▪ Comparative analysis of differing statin therapies in the management of severe LDL dyslipidemia.
   Google Scholar
• Postiglione A, Montefusco S, Pauciullo P, Mancini M, Piliego T: Effects of atorvastatin in patients with homozygous familial hypercholesterolemia. Atherosclerosis 147(2), 423–424 (1999).
   Google Scholar
• Nawrocki JW, Weiss SR, Davidson MH et al.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15(5), 678–682 (1995).
   Google Scholar